Immunochemotherapy With Rituximab-Bendamustine-Cytarabine (R-BAC) for Patients With Mantle Cell Lymphoma
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
The objective of the study is to demonstrate the safety, tolerability, and activity of
Rituximab-Bendamustine-Cytarabine(R-BAC) regimen in patients with mantle cell lymphoma (MCL)
aged 65 years or more, as well as in younger patients who are not eligible for intensive
regimens including/not including autologous transplantation.